Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$1.61 – $8.81
22% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $5.6M | $4.3M | $5.7M | $5.0M | $5.2M | $0 | $0 |
| Cost of revenue | $5.4M | $4.0M | $7.2M | $4.3M | $4.3M | $5.2M | $0 | $0 |
| Gross profit | $378.4K | $1.6M | −$2.9M | $1.3M | $680.8K | −$4.5K | $0 | $0 |
| Gross margin | 6.5% | 28.4% | -66.9% | 23.4% | 13.7% | -0.1% | — | — |
| R&D | $1.3M | $1.2M | $3.6M | $11.7M | $6.8M | $5.2M | $1.2M | $184.8K |
| Operating income | −$1.1M | −$1.5M | −$12.7M | −$22.7M | −$17.9M | −$11.3M | −$5.8M | −$13.2M |
| EBITDA | −$717.9K | −$1.3M | −$11.2M | −$22.3M | −$13.8M | −$11.3M | −$5.2M | −$13.2M |
| Net income | −$1.2M | −$1.8M | −$20.4M | −$17.9M | −$21.0M | −$13.4M | −$6.2M | −$19.5M |
| Net margin | -20.7% | -32.2% | -474.2% | -316.6% | -422.1% | -257.8% | — | — |
| EPS (diluted) | -2.26 | -2.85 | -7.89 | -6.10 | -5.48 | -2.46 | -17.28 | -8.11 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds QLGN.
No tracked institution reports a position in QLGN as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-11-05 | 1-for-50reverse |
| 2022-11-23 | 1-for-10reverse |
| 2018-03-23 | 1-for-10reverse |
No one on the platform has traded QLGN yet.
| $3M |
| — |
| KALAKALA BIO, Inc. | $2.09 | -17.06% | $46M | — |
| KZIAKazia Therapeutics Ltd ADR | $14.46 | +1.69% | $23M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at NaN× sales vs its 188.3× historical median P/S.
Fair value ≈ $0.00 · price $3.21 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.